^
Association details:
| Biomarker: | ETV6-NTRK3 fusion |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition
Excerpt:
Etv6-NTRK3/+;CD19-Cre cells isolated from bone marrow and cultured ex vivo also showed exquisite sensitivity to both larotrectinib and PLX7486 (Figure 2B).
DOI:
10.1182/blood-2018-05-849554
